A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study of Etanercept on a Background Non Steroidal Anti-Inflammatory Drug in the Treatment of Adult Subjects With Non Radiographic Axial Spondyloarthritis With a 92 Week Open Label Extension

Trial Profile

A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study of Etanercept on a Background Non Steroidal Anti-Inflammatory Drug in the Treatment of Adult Subjects With Non Radiographic Axial Spondyloarthritis With a 92 Week Open Label Extension

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms AS EARLY; EMBARK
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Feb 2018 Results comparing 2 years of radiographic sacroiliac joint (SIJ) changes in EMBARK and DESIR trials published in the Annals of the Rheumatic Diseases
    • 08 Nov 2017 Results assessing the impact of sustained clinical remission on MRI structural parameters in patients with early axial Spa (EMBARK; n=150 and DESIR; n=68 trials), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 17 Jun 2017 Results (n=361) of a study assessing change in sacroiliac joint structural radiographic damage after 2 years of Etanercept using patient data from NCT01258738 and NCT01648907 trials, presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top